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Dr. Brandenburg: Dr. Fuster, in your discussion on the
development of the atherosclerotic lesion, fat is not men-
tioned until the fifth stage. Does this fact have something
to do with the rather disappointing effects of fat reduction
in the diet for controlling the problem of atherosclerosis?
Dr. Fuster: There are five biological ways in which fat
plays important roles in the atherosclerotic process.
1. A high serum concentration of low density lipoprotein
appears to contribute to the process of endothelial injury.
2. Some studies with smooth muscle cell cultures suggest
that lipoproteins may be mitogenic, contributing to cell
membrane formation.
3. The space occupying fat accumulations may contribute
to the growth of the atherosclerotic plaque.
4. Factors impairing removal of cholesterol from the arterial
wall appear to favor its accumulation and, hence, pro-
gression of the disease.
5. Evidence has been presented indicating lipoproteins may
enhance platelet reactivity explaining the increased
thrombogenicity of an ulcerated plaque.
In addition to the biological process, there are the epi-
demiologic aspects in a disease like atherosclerosis.
Dr. Brandenburg: Dr. Reeves, what is your approach to
the patient with mild stable angina pectoris whose echo-
cardiogram discloses normal left ventricular function? Are
additional studies indicated?
Dr. Reeves: I would like to see the results of a stress
test. Also, exercise echocardiography is being developed.
Dr. Oliver: With respect to the role of lipids in athero-
sclerosis, studies of twins indicate that 55 to 59% of the
cholesterol level is genetically determined. In view of this,
we must take into account the other aspects of the genetic
transmission of lipoprotein abnormalities. Perhaps the endo-
thelial receptor systems have been underemphasized.
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Dr. Meijler: Dr. Fuster, why do many people who do
not develop unstable angina, myocardial infarction or sud-
den death seem to lead the same type of life as those who
do?
Dr. Fuster: Most investigators consider atherosclerotic
disease a biological reaction of the artery to chronic injury.
Early lesions are seen at autopsy in almost everyone older
than the age of 40 to 50 years. However, only selected
people develop clinically important lesions. Young patients
who have clinically significant coronary artery disease al-
most invariably have a strong family history of first degree
relatives with coronary artery disease and have a very high
incidence of being cigarette smokers. These factors appear
to accelerate the disease process. However, it is certainly
true that individuals aged 60 to 65 years who have a myo-
cardial infarction may have no risk factors.
Dr. Rossi: With respect to the classification of cardio-
myopathies, I would mention so-called right ventricular dys-
plasia. I believe that since this is an acquired disease of
unknown cause, we could call it RVD, but interpret the
"D" as disease, rather than dysplasia.
Dr. Hinkle: In the Coronary Artery Surgery Study
(CASS), prognosis was related first to the functional state
of the left ventricle, but beyond that it was related to the
number of vessels occluded, the degree of occlusion and
the location of the occlusion. Angina pectoris, whether pres-
ent or absent, was not an independent indicator of risk. In
view of this, Dr. Reeves, what would the indication be for
performing coronary angiography if there was no angina
pectoris and no evidence of impaired left ventricularfunction?
Dr. Reeves: I draw attention to the study of Kent and
Epstein in patients with triple vessel disease who were
asymptomatic or only mildly symptomatic and had normal
ventricular function. In the high risk group with a shortened
exercise stress test, the annual mortality rate could be as
high as 9%.
Dr. Hinkle: I was referring to a population group of
individuals and trying to determine how to identify people
with significant coronary artery disease. I gather this would
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be done primarily by noting abnormalities in the rest elec-
trocardiogram or obtaining a stress test.
Dr. Reeves: In addition , I would identify major risk fac-
tors such as a strong family history of coronary disease ,
cigarette smoking and hypertension .
Dr. Titus: Minimal thickening of the arterial wall should
not be termed atherosclerosis . This term is appropriate only
when there has been progre ssion beyond the thickening.
(Dr. Fuster agreed .)
Dr. Gersh: I am pleased to hear Dr. Fuster make a strong
argument in support of sudden death in many instances
masking the underlying or precipitating event. Perhaps in
determining the therapeutic strategy for sudden death, one
of the major considerations would be that active ischemia,
either overt or covert, is present.
Questionfrom the audience: How would you rationalize
therapy for patients who have postinfarction angina, partic-
ularly in regard to anticoagulation?
Dr. Fuster: In the effort to prevent myocardial infarction ,
platelet inhibitor therapy would seem appropriate where there
are rapid changes in the atherosclerotic lesion and in patients
with unstable angina. In patients with unstable angina , three
studies-a European study of heparin , a U.S . study of as-
pirin and a Canadian study of aspirin-disclosed the same
result. There was a 50 to 60% reduction in the incidence
of myocardial infarction or sudden death within 12 weeks .
This is the group of patients that I believe should receive
antithrombotic therapy. The duration of this therapy is not
yet clear. I do not advise the use of platelet inhibitor drugs
in patients with chronic coronary artery disease.
